ETadmin, Author at Elevar Therapeutics

Director Clinical Strategic Development

October 26, 2018

Director Clinical Strategic Development LSK Biopharma South San Francisco, CA Director Clinical Strategic Development (CSD) provides critical expertise and leadership in the design and planning of integrated development plans for multiple disease indications. CSD drives adoption of innovative approaches and strategic thinking in

LSK BioPharma and Jiangsu Hengrui Medicine Announce Global Clinical Collaboration to Evaluate the Combination of Anti-Angiogenesis and Immuno-Oncology Therapy for Patients with Advanced Hepatocellular Carcinoma (HCC)

October 21, 2018

SALT LAKE CITY, USA, and SHANGHAI, CHINA, October 21, 2018 -- LSK BioPharma (or “LSKB”), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or “Hengrui”), one of the largest and most innovative fully-integrated biopharmaceutical companies based in

LSKB Announces MFDS Approval to Initiate a Phase I/IIa Combination Study of Rivoceranib and Paclitaxel at Asan Medical Center (South Korea)

October 1, 2018

SALT LAKE CITY, USA, Oct 1st, 2018 -- LSK BioPharma (LSKB, Company) announced that the South Korean Ministry of Food and Drug Safety (MFDS) has approved a Phase I/IIa study protocol to investigate the combination of rivoceranib and paclitaxel, “A

Senior Clinical Study Manager

August 1, 2018

Ensure that global regulated clinical studies are compliant and that clinical trials are conducted with company goals, SOPs, Ethics, ICH GCP and global regulatory guidelines. Provide operations management for the planning, execution and reporting of Phase III global clinical trials.

LSKB Announces that Enrollment has Opened at Huntsman Cancer Institute for the APPEASE Study combining Rivoceranib and Pembrolizumab

June 19, 2018

SALT LAKE CITY, USA, June 19, 2018 -- LSK BioPharma (LSKB, Company) announced that enrollment has opened for the APPEASE study, “A phase 1/2 open label study of the safety and efficacy of apatinib [rivoceranib] administered to patients with advanced

Preclinical/DMPK Research Associate

June 19, 2018

Position Scope and Summary LSK BioPharma is searching for a qualified candidate to join our preclinical product development team in South San Francisco. The position will be responsible for planning and monitoring preclinical and DMPK-related projects performed by LSK BioPharma’s vendors/contractors. Roles

CMC Product Manager

June 13, 2018

Overview We are currently seeking a full-time, office-based CMC Product Manager to join LSK Biopharma. This position will manage and guide our CMC activities for our small molecule drug substance and product programs from preclinical through commercial. If you want an

Regulatory Affairs – Submissions Project Senior Manager/Director

May 14, 2018

Overview We are currently seeking a full-time, office-based Regulatory Affairs Manager/Director to join LSK Biopharma. This position will work with our clinical and product development teams to contribute to the strategic planning and preparation of regulatory submissions and supports the formatting,

LSKB TO REPORT NON-CLINICAL RIVOCERANIB (APATINIB) COMBINATION WITH IMMUNOTHERAPY

April 16, 2018

SALT LAKE CITY, April 16, 2018 – LSK BioPharma (LSKB) today will present a poster at the American Association for Cancer Research (AACR) Annual Meeting in Chicago. The poster discloses nonclinical data suggesting a synergistic combination of rivoceranib (apatinib) with

Part Time Contract – Senior CRA position

March 7, 2018

Position has been filled. Responsibilities and Duties Essential Duties & Responsibilities: Primary contact for the site, supervise and monitor clinical trials to ensure adherence to ICH-GCP standards, study protocol, SOPs and regulations. Ensure proper adherence to protocol, Informed consent procedures, source

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_J9N59KKZLK	2 years	This cookie is installed by Google Analytics.

Pencil Banner Copy AUGUST2023

Author: ETadmin